Loading…

908 Devices Inc.MASSCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum strong 65
Mkt cap
$396M
US dollars, full cap
Free float
79%
of shares outstanding
$/day
$4.08M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-40.0 pp
WACC 8.3%
Hurdle
+26 pp
Req g minus delivered
Next earnings
111 days
9 Mar 2027
Close · USD$9.52
1D+1.4%
1W-5.4%
1M-17.3%
3M-8.0%
6M+36.4%
YTD+81.3%
1Y+77.0%
ATR %8.3%
Beta1.87
52w lowhigh28.7% off high

What 908 Devices does

Employees: 172

908 Devices at a glance

Size 908 Devices (MASS) is a United States Health Care company (Medical Specialties) with a market value of $396M, the 2841st largest of 3,085 United States companies the cockpit tracks. Shares closed at $9.52 on 18 Nov 2026.

Performance Over six months the shares gained 36.4%, against -25.6% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.

Growth Revenue grew 14.1% over the last twelve months (peer median +14.5%); the operating margin is -33.2% (peer median 9.3%).

Valuation It trades at 4.6× enterprise value to sales against a peer median of 3.9× (8th most expensive of 20).

Price implies For today's price to make sense, revenue must grow about 42% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 40.0 points below its cost of capital (8.3% WACC).

Backlog Backlog (remaining performance obligations) was $22.9M at 30 Sep 2026, up 25% on a year earlier — 0.3 years of trailing revenue. Backlog detail →

Short interest Short interest is 6.2% of the free float (30 Oct 2026).

Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026MASS 134Peer median 75
Six months, rebased to 100: 908 Devices against the median of its 20 peers (local-currency closes).

908 Devices financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$65.8M$56.2M$47.7M$50.2M$46.9M
Revenue growth—+18%-5%+7%—
Gross profit$32.1M$26.8M$21.5M$23.4M$24.6M
EBITDA-$16.7M-$19.7M-$25.3M-$40.0M-$33.6M
Net income-$24.2M-$36.6M-$72.2M-$36.4M-$33.6M
Free cash flow$2.50M-$24.6M-$30.8M-$27.1M-$23.0M
Capital expenditure$261,000$955,000$602,000$2.04M$2.04M
Total debt$5.05M$4.63M$4.07M$5.95M$19.5M

Quarterly statements and history in the cockpit →

908 Devices competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-40%-20%0%3002386929458870CERS00202268813347360418306051866748301097300562BWAY1763CVMASS6-month return →1-month return →
Up and to the right = strong over both horizons. 908 Devices is the large dot.

Fundamentals: revenue growth against valuation

0%+250%+500%+750%+1,000%0×100×200×300238692945887098776748CVMASSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. 908 Devices is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%692945887047366883582041BWAYMASSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. 908 Devices is the large dot.

908 Devices competitors and peer comparison

How 908 Devices compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

908 Devices against its 20 peers (data as of 18 Nov 2026)
MeasureMASSPeer medianRank in peer set
1-month return-17.3%-11.5%5th lowest of 21
6-month return+36.4%-25.6%2nd highest of 20
Distance from 52-week high-28.7%-45.5%3rd highest of 21
Revenue growth (TTM)+14.1%+14.5%11th highest of 21
Operating margin-33.2%9.3%5th lowest of 21
EV / Sales4.6×3.9×8th most expensive of 20
Growth the price implies (Req g, 7 yrs)41.7%-2.2%most demanding of 11
Growth delivered (Del g)+15.9%+15.5%5th highest of 11
Hurdle (Req g minus delivered)+25.8 pp-2.0 ppmost demanding of 11
ROIC minus cost of capital-40.0 pp-1.2 pp3rd lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
908 Devices MASSUnited States$396M+36%+14%-33%4.6×41.7%+15.9%
Guanhao Biotech 300238.SZChina$397M-26%-12%3%7.1×n/an/a
OrbusNeich Medical 6929.HKHong Kong$394M-15%+16%23%1.0×-17.6%+15.4%
SEERS 458870.KSSouth Korea$392M-70%+174%37%5.5×-6.3%+247.0%
Cerus CERSUnited States$392M-28%+14%-12%1.8×n/an/a
Shanghai Kehua Bio-Engineering 002022.SZChina$389M-14%+7%-40%1.7×n/an/a
Shanghai Titan Scientific 688133.SSChina$403M-26%+1%-6%1.4×n/an/a
Taidoc Technology 4736.TWTaiwan$387M0%0%19%1.8×-9.5%-6.6%
Chison Medical Technologies 688358.SSChina$406M-27%-1%19%3.9×9.6%+5.6%
InBody 041830.KSSouth Korea$380M-13%+22%22%1.4×-10.3%+16.9%
Shanghai General Healthy Information & Technology 605186.SSChina$379M-26%-11%5%7.8×n/an/a
Medcaptain Medical Technology 2041.HKHong Kong$378Mn/a+19%2%1.5×17.1%+18.1%
Jenscare Scientific 9877.HKHong Kong$415M-32%+993%-106%17.8×n/an/a
ACRO Biomedical 6748.TWOTaiwan$377M+158%+45%-178%218.3×n/an/a
Ningbo Tianyi Medical Appliance 301097.SZChina$418M-22%+46%8%4.4×n/an/a
Guangdong Transtek Medical Electronics 300562.SZChina$373M-15%+7%11%1.8×-4.2%-6.0%
Brainsway Ltd Sponsored ADR BWAYUnited States$373M-41%+32%14%4.8×24.9%+18.8%
Hunan Sundy Science and Technology 300515.SZChina$425M-16%+10%27%3.5×-0.1%+15.6%
China Isotope & Radiation 1763.HKHong Kong$428M-41%-5%13%n/an/an/a
Revenio REG1V.HEFinland$428M-34%+44%10%4.0×18.5%+12.4%
CapsoVision CVUnited States$366M+5%+15%-213%24.8×n/an/a

908 Devices backlog

908 Devices reported $22.9M of remaining performance obligations at 30 Sep 2026, up 25% from a year earlier and up 6% from the previous quarter. That is 0.3 years of trailing revenue already under contract. Book-to-bill last quarter: 1.06.

Questions

Which companies are 908 Devices's closest peers?
The cockpit's peer set: Guanhao Biotech (300238.SZ), OrbusNeich Medical (6929.HK), SEERS (458870.KS), Cerus (CERS), Shanghai Kehua Bio-Engineering (002022.SZ), Shanghai Titan Scientific (688133.SS), Taidoc Technology (4736.TW), Chison Medical Technologies (688358.SS).
Is 908 Devices expensive compared with its peers?
On ev / sales it trades at 4.6× against a peer median of 3.9×, 8th most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about 42% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has 908 Devices stock performed?
Over six months to 18 Nov 2026 the shares returned +36.4% against -25.6% for the median peer; over one year +77.0%.
What is 908 Devices's backlog?
908 Devices's remaining performance obligations (contracted revenue not yet recognised) were $22.9M at 30 Sep 2026, +25% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.